BACKGROUND: Cardiac troponin (cTn) has been established as an effective prognostic marker in acute heart failure (HF) with predominantly reduced ejection fraction. However, it's prognostic value in heart failure with preserved ejection fraction (HFpEF) is unclear. The aim of this study is to describe the prognostic role of troponin I in patients hospitalized for HFpEF decompensation. METHODS: We included 363 consecutive patients admitted for HFpEF decompensation that was not associated with acute coronary syndrome (ACS). Patients with troponin level elevation (troponin I level ≥0.04 ng/mL) were compared to patients with normal troponin level. The primary outcome was short-, intermediate-, and long-term all-cause mortality. The secondary outcomes were differences in B-type natriuretic peptide level (BNP), length of stay, and readmission rates between the two groups. RESULTS: Nearly half of the patients in the Cohort had troponin level elevation. Troponin level elevation was significantly associated with higher 30-day (4.8% vs. 0.6%, P=0.014), 1-year (12.2% vs. 4.6%, P=0.009), and 2-year mortality (13.8% vs. 5.1%, P=0.005) when compared to a normal troponin level. Troponin level elevation was an independent predictor of mortality after adjusting for clinical and laboratory risk factors seen in HFpEF decompensation. Additionally, BNP level >287 pg/mL, age, and history of atrial fibrillation were identified as statistically significant predictors of mortality. CONCLUSIONS: Troponin level elevation, in hospitalized patients with HFpEF decompensation, was associated with higher short-, intermediate-, and long-term mortality.
BACKGROUND: Cardiac troponin (cTn) has been established as an effective prognostic marker in acute heart failure (HF) with predominantly reduced ejection fraction. However, it's prognostic value in heart failure with preserved ejection fraction (HFpEF) is unclear. The aim of this study is to describe the prognostic role of troponin I in patients hospitalized for HFpEF decompensation. METHODS: We included 363 consecutive patients admitted for HFpEF decompensation that was not associated with acute coronary syndrome (ACS). Patients with troponin level elevation (troponin I level ≥0.04 ng/mL) were compared to patients with normal troponin level. The primary outcome was short-, intermediate-, and long-term all-cause mortality. The secondary outcomes were differences in B-type natriuretic peptide level (BNP), length of stay, and readmission rates between the two groups. RESULTS: Nearly half of the patients in the Cohort had troponin level elevation. Troponin level elevation was significantly associated with higher 30-day (4.8% vs. 0.6%, P=0.014), 1-year (12.2% vs. 4.6%, P=0.009), and 2-year mortality (13.8% vs. 5.1%, P=0.005) when compared to a normal troponin level. Troponin level elevation was an independent predictor of mortality after adjusting for clinical and laboratory risk factors seen in HFpEF decompensation. Additionally, BNP level >287 pg/mL, age, and history of atrial fibrillation were identified as statistically significant predictors of mortality. CONCLUSIONS: Troponin level elevation, in hospitalized patients with HFpEF decompensation, was associated with higher short-, intermediate-, and long-term mortality.
Authors: Robb D Kociol; Peter S Pang; Mihai Gheorghiade; Gregg C Fonarow; Christopher M O'Connor; G Michael Felker Journal: J Am Coll Cardiol Date: 2010-09-28 Impact factor: 24.094
Authors: Frank P Brouwers; Rudolf A de Boer; Pim van der Harst; Adriaan A Voors; Ron T Gansevoort; Stephan J Bakker; Hans L Hillege; Dirk J van Veldhuisen; Wiek H van Gilst Journal: Eur Heart J Date: 2013-03-06 Impact factor: 29.983
Authors: Domingo A Pascual-Figal; Sergio Manzano-Fernández; Miguel Boronat; Teresa Casas; Iris P Garrido; Juan C Bonaque; Francisco Pastor-Perez; Mariano Valdés; James L Januzzi Journal: Eur J Heart Fail Date: 2011-05-06 Impact factor: 15.534
Authors: R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu Journal: N Engl J Med Date: 2006-07-20 Impact factor: 91.245
Authors: Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald Journal: JAMA Date: 2013-03-27 Impact factor: 56.272
Authors: Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren Journal: Lancet Date: 2003-09-06 Impact factor: 79.321
Authors: Rajalakshmi Santhanakrishnan; Jenny P C Chong; Tze P Ng; Lieng H Ling; David Sim; Kui Toh G Leong; Poh Shuan D Yeo; Hean Y Ong; Fazlur Jaufeerally; Raymond Wong; Ping Chai; Adrian F Low; Arthur Mark Richards; Carolyn S P Lam Journal: Eur J Heart Fail Date: 2012-08-05 Impact factor: 15.534
Authors: Barry M Massie; Peter E Carson; John J McMurray; Michel Komajda; Robert McKelvie; Michael R Zile; Susan Anderson; Mark Donovan; Erik Iverson; Christoph Staiger; Agata Ptaszynska Journal: N Engl J Med Date: 2008-11-11 Impact factor: 91.245
Authors: Marat Fudim; Andrew P Ambrosy; Jie-Lena Sun; Kevin J Anstrom; Bradley A Bart; Javed Butler; Omar AbouEzzeddine; Stephen J Greene; Robert J Mentz; Margaret M Redfield; Yogesh N V Reddy; Muthiah Vaduganathan; Eugene Braunwald; Adrian F Hernandez; Barry A Borlaug; G Michael Felker Journal: J Am Heart Assoc Date: 2018-12-18 Impact factor: 5.501